Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN, Terpos E, Papanagnou ED, Kastritis E, Brieudes V, Halabalaki M, Bagratuni T, Florea BI, Overkleeft HS, Scorrano L, Skaltsounis AL, Dimopoulos MA, Trougakos IP.
Tsakiri EN, et al. Among authors: trougakos ip.
Sci Rep. 2017 Dec 19;7(1):17802. doi: 10.1038/s41598-017-17596-4.
Sci Rep. 2017.
PMID: 29259189
Free PMC article.